tiprankstipranks
Advertisement
Advertisement

Bafna Pharmaceuticals Announces Board and Committee Restructuring

Story Highlights
Bafna Pharmaceuticals Announces Board and Committee Restructuring

Elevate Your Investing Strategy:

The latest update is out from Bafna Pharmaceuticals Limited ( (IN:BAFNAPH) ).

Bafna Pharmaceuticals Limited announced the retirement of Mr. Palamadai Krishnan Sundaresan as an Independent Director, effective June 24, 2025. This change led to the reconstitution of the Audit and Nomination & Remuneration Committees, ensuring continued compliance with regulatory requirements. The new committee members include Mr. Navin Kumar as Chairman of the Audit Committee and Mrs. Ravichandran Chitra as Chairperson of the Nomination and Remuneration Committee. Despite the changes, the board and its committees remain in compliance with applicable laws, maintaining stability in the company’s governance structure.

More about Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the manufacturing and distribution of pharmaceutical products. The company is based in Chennai, India, and is known for its commitment to quality and compliance with industry regulations.

Average Trading Volume: 1,035

Current Market Cap: 1.75B INR

Learn more about BAFNAPH stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1